Compare LULU & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LULU | GMAB |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | Canada | Denmark |
| Employees | N/A | 3029 |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 16.9B |
| IPO Year | 2007 | N/A |
| Metric | LULU | GMAB |
|---|---|---|
| Price | $166.59 | $27.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 8 |
| Target Price | ★ $190.26 | $39.81 |
| AVG Volume (30 Days) | ★ 2.0M | 1.6M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.26 | N/A |
| Revenue | ★ $11,102,600,000.00 | N/A |
| Revenue This Year | $5.52 | $17.85 |
| Revenue Next Year | $4.68 | $16.04 |
| P/E Ratio | $12.58 | ★ $1.90 |
| Revenue Growth | ★ 4.86 | N/A |
| 52 Week Low | $143.96 | $18.89 |
| 52 Week High | $340.25 | $35.43 |
| Indicator | LULU | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 43.42 |
| Support Level | $159.83 | $24.95 |
| Resistance Level | $171.31 | $29.64 |
| Average True Range (ATR) | 5.50 | 0.58 |
| MACD | 1.74 | 0.06 |
| Stochastic Oscillator | 80.72 | 17.01 |
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.